Zura Bio’s (ZURA) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Zura Bio (NASDAQ:ZURA) in a report published on Friday morning, Benzinga reports.

A number of other research firms have also recently commented on ZURA. Piper Sandler reissued an “overweight” rating and issued a $26.00 price target on shares of Zura Bio in a report on Thursday, September 19th. HC Wainwright assumed coverage on shares of Zura Bio in a research report on Thursday, September 5th. They issued a “neutral” rating and a $5.00 price objective for the company.

Zura Bio Stock Down 1.8 %

Shares of Zura Bio stock opened at $4.83 on Friday. Zura Bio has a 52-week low of $2.00 and a 52-week high of $6.35. The firm’s 50 day moving average price is $3.92 and its 200-day moving average price is $3.96.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). On average, equities research analysts forecast that Zura Bio will post -0.47 EPS for the current fiscal year.

Insider Buying and Selling at Zura Bio

In other news, Director Someit Sidhu sold 51,728 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the transaction, the director now directly owns 2,085,418 shares in the company, valued at $8,070,567.66. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 15.80% of the company’s stock.

Institutional Investors Weigh In On Zura Bio

Several hedge funds have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. purchased a new position in shares of Zura Bio during the 2nd quarter valued at about $8,446,000. Great Point Partners LLC raised its position in Zura Bio by 68.3% during the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after acquiring an additional 1,884,501 shares in the last quarter. Armistice Capital LLC raised its position in Zura Bio by 53.2% during the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after acquiring an additional 876,000 shares in the last quarter. Affinity Asset Advisors LLC acquired a new position in Zura Bio in the first quarter valued at approximately $1,157,000. Finally, SG Americas Securities LLC purchased a new stake in Zura Bio in the 3rd quarter worth approximately $62,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.